Cargando…
Hemoglobin‐platelet index as a prognostic factor in patients with peripheral T‐cell lymphoma
Peripheral T‐cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas with a poor prognosis. The International Prognostic Index (IPI) and the Prognostic Index for PTCL‐unspecified (PIT) is used to predict the prognosis of PTCL. The hemoglobin‐platelet index (HPI), based on anemia and th...
Autores principales: | Yagi, Yu, Kanemasa, Yusuke, Sasaki, Yuki, Okumura, Shunichi, Watanabe, Takako, Ishimine, Kento, Hayashi, Yudai, Mino, Mano, Ohigashi, An, Morita, Yuka, Tamura, Taichi, Nakamura, Shohei, Okuya, Toshihiro, Shimoyama, Tatsu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435682/ https://www.ncbi.nlm.nih.gov/pubmed/37601871 http://dx.doi.org/10.1002/jha2.727 |
Ejemplares similares
-
P1153: UTILITY OF THE FRAILTY SCORE FOR PREDICTING PROGNOSIS AND INDIVIDUALIZING TREATMENT INTENSITY IN ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Yagi, Yu, et al.
Publicado: (2023) -
Clinical outcomes in transplant‐eligible patients with relapsed or refractory diffuse large B‐cell lymphoma after second‐line salvage chemotherapy: A retrospective study
por: Yagi, Yu, et al.
Publicado: (2023) -
Pevonedistat, a NEDD8‐activating enzyme inhibitor, induces apoptosis and augments efficacy of chemotherapy and small molecule inhibitors in pre‐clinical models of diffuse large B‐cell lymphoma
por: Torka, Pallawi, et al.
Publicado: (2020) -
Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020) -
Plasma thymus and activation‐regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2020)